source
- Skyhawk Therapeutics reports symptom improvement for Huntington's disease in Phase 1/2 extension studySkyhawk Therapeutics announced that its RNA-splicing candidate SKY-0515 showed a measurable improvement in symptoms for patients with Huntington's disease during an extension of its Phase 1/2 trial…
- Novo Nordisk partners with Anthropic to boost drug discovery using Claude Science AINovo Nordisk announced a collaboration with Anthropic aimed at accelerating the discovery and development of new medicines through artificial intelligence. The two companies will test Anthropic's…